Royalty Pharma plc (RPRX) Current Ratio
- Current ratio · latest quarter: Value 2.80×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.80× | Current assets / current liabilities. $1.76B ÷ $630.93M ≈ 2.80× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.76B USD | Assets, Current |
| Current obligations | 630.93M USD | Liabilities, Current |
| Cash and equivalents | 811.99M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 25.00M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | (m) | |
| Borrowing debt due within one year | 380.00M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.76B | $630.93M | $811.99M | $25.00M | (m) | (m) | (m) | $380.00M | 2.80× |
| 2026-03-31 | $1.43B | $535.68M | $586.39M | $21.90M | (m) | (m) | (m) | $380.00M | 2.66× |
| 2025-12-31 | $1.53B | $636.21M | $618.70M | $18.80M | (m) | (m) | (m) | $380.00M | 2.40× |
| 2025-09-30 | $1.85B | $530.80M | $938.94M | $16.10M | (m) | (m) | (m) | $380.00M | 3.48× |
| 2025-06-30 | $1.52B | $1.21B | $631.91M | $13.20M | (m) | (m) | (m) | $999.44M | 1.26× |
| 2025-03-31 | $1.84B | $1.18B | $1.09B | $12.10M | (m) | (m) | (m) | $998.61M | 1.56× |
| 2024-12-31 | $1.80B | $1.25B | $929.03M | $58.20M | (m) | (m) | (m) | $997.77M | 1.44× |
| 2024-09-30 | $1.79B | $1.17B | $950.05M | $48.50M | (m) | (m) | (m) | $996.94M | 1.54× |
| 2024-06-30 | $2.58B | $275.70M | $1.76B | $38.50M | (m) | (m) | (m) | $0.00 | 9.35× |
| 2024-03-31 | $1.56B | $124.57M | $843.00M | $29.00M | (m) | (m) | (m) | $0.00 | 12.52× |
| 2023-12-31 | $1.27B | $161.38M | $477.01M | $18.30M | (m) | (m) | (m) | $0.00 | 7.90× |
| 2023-09-30 | $1.73B | $127.93M | $936.45M | $5.30M | (m) | (m) | (m) | $0.00 | 13.51× |
| 2023-06-30 | $2.95B | $1.17B | $2.17B | $5.10M | (m) | (m) | (m) | $999.37M | 2.52× |
| 2023-03-31 | $2.63B | $1.12B | $1.98B | $2.50M | (m) | (m) | (m) | $998.44M | 2.36× |
| 2022-12-31 | $2.55B | $1.17B | $1.71B | $1.30M | (m) | (m) | (m) | $997.51M | 2.19× |
| 2022-09-30 | $2.34B | $1.13B | $991.63M | $409.35M | (m) | (m) | (m) | $996.58M | 2.07× |
| 2022-06-30 | $3.50B | $182.33M | $2.11B | $363.70M | (m) | (m) | (m) | $0.00 | 19.22× |
| 2022-03-31 | $2.98B | $135.87M | $1.79B | $64.80M | (m) | (m) | (m) | $0.00 | 21.95× |
| 2021-12-31 | $2.88B | $171.25M | $1.54B | $66.00M | (m) | (m) | (m) | $0.00 | 16.81× |
| 2021-09-30 | $2.78B | $255.06M | $1.80B | $67.02M | (m) | (m) | (m) | $0.00 | 10.88× |
| 2021-06-30 | $2.71B | $283.99M | $1.14B | $68.70M | (m) | (m) | (m) | $0.00 | 9.53× |
| 2021-03-31 | $2.42B | $255.98M | $708.81M | $69.26M | (m) | (m) | (m) | $0.00 | 9.44× |
| 2020-12-31 | $2.70B | $307.89M | $1.01B | $69.98M | (m) | (m) | (m) | $0.00 | 8.76× |
| 2020-09-30 | $2.78B | $269.98M | $1.55B | $43.51M | (m) | (m) | (m) | $0.00 | 10.31× |
| 2020-06-30 | $3.39B | $450.97M | $2.44B | $28.50M | (m) | (m) | (m) | $182.23M | 7.52× |
| 2019-12-31 | $832.07M | $333.42M | $246.20M | $0.00 | (m) | (m) | (m) | $281.98M | 2.50× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |